“The pill” may be easier to obtain in the United States in the near future

“The pill” may be easier to obtain in the United States in the near future

Oral contraceptives (OCs), known commonly as “the pill,” are prescription medications that prevent pregnancy. The most common brands of OCs contain hormone combinations of estrogen, progestin, and/or progesterone. These products have been used for years and were first launched on the U.S. prescription market in the 1960s. While OCs resulted in a new era of pregnancy protection for women, they were not without potential side effects to be considered, including risk of blood clots, heart attack, stroke, high blood pressure, and breast cancer (particularly for women who smoke). To date, OCs have proven to be one of the most popular forms of birth control, due to ease of use, efficacy, and their good safety profile for most women. Continue reading

Consumers’ perception of sleep aids: OTCs, natural products, and devices

Consumers’ perception of sleep aids: OTCs, natural products, and devices

The number of consumers suffering from sleeping disorders continues to grow, and quality sleep is a major issue for many Americans.

  • According to the National Center for Sleep Disorders Research at the National Institutes of Health, about 30% to 40% of adults have some symptoms of insomnia within a given year, and about 10% to 15% of adults claim to have chronic insomnia.
  • People over the age of 65 years are 1.5 times more likely to suffer from insomnia as compared to younger people.
  • According to American Sleep Association, every year, approximately 40 million Americans, if not more, are afflicted by chronic long-term sleep disorders.
  • Insomnia is considered a serious ailment, as it can lead to several other health-related problems, such as depression, as well as heart disease.

Continue reading

Industry consolidation impacts OTC market

Consolidated U.S. OTC market sees leading players shift

The top six branded OTC marketers in the United States hold 37% of the total market, and many of these companies have grown as a result of consolidation and acquisitions over the past five years.

Bayer’s acquisition of Merck’s consumer health unit bolstered its position from #3 in 2011 to now being the #1 marketer in the United States. GlaxoSmithKline’s rank improved from #6 in 2011 to #3 in 2016 with the addition of Novartis’ OTC unit via a joint venture. Sanofi’s acquisition of Boehringer-Ingelheim’s consumer health unit helped it jump from #9 in 2011 to #6 in 2016. Continue reading

Nonprescription Drugs USA

Webinar Next Week: Key Issues Trending in the OTC Market

The U.S. OTC industry witnesses another year of growth with categories like topical analgesics, internal analgesics, herbal products, nasal allergy sprays, and contraceptive products all experiencing stronger than average sales growth.

What’s behind this growth? What are the latest developments? What is the impact of recently approved switches? We will reveal it all during this live webinar drawing upon highlights from our preeminent Nonprescription Drugs USA, Digestive Health, Immunity, and Probiotics: U.S. Market Analysis and Opportunities, and Rx-to-OTC Switch Forecasts USA: Next Frontier studies.Continue reading

U.S. Nonprescription Drugs Industry

Healthy Growth of the U.S. Nonprescription Drugs Industry Projected to Continue

Findings from the recently published Nonprescription Drugs USA study show positive signs of growth for the 2013 U.S. OTC market. Compared to 2012 when the market had flat sales performance, 2013 recorded healthy growth of 3.0% to reach $23.5 billion at the manufacturers’ level. The market is driven by the strong performance of several brands including Novartis’ Excedrin and Johnson & Johnson’s Tylenol and Motrin IB, as well as the continuous strong sales performance coming from nutritional brands, such as Vitafusion (Church & Dwight), Centrum (Pfizer), and Schiff (Reckitt Benckiser).Continue reading

Sales Resurgence of U.S. OTCs in 2013 Helps the Market Overcome Flat Sales Performance of the Past

Sales Resurgence of U.S. OTCs in 2013 Helps the Market Overcome Flat Sales Performance of the Past

According to Kline’s Nonprescription Drugs USA  study, the U.S. OTC market grew over 3.0% during 2013 to reach $23.5 billion at the manufacturers’ level.  Driven by strong sales gains in analgesics, upper respiratory, nutritional, and topical products, the market appears to be showing signs of recovery. This is partly due to the long-awaited rejuvenation of several brands that have posted steep declines in the recent past as a result of supply disruptions and recalls. Brands such as Novartis’ Excedrin and Johnson & Johnson’s Tylenol and Motrin IB have experienced strong gains in 2013 thereby helping the analgesics category to post very strong gains this past year while Pfizer’s Advil, Bayer’s Aleve, and private-label analgesics also posted gains in 2013. Continue reading

FDA Initiative Forms Basis for Healthy Rx-to-OTC Switch Opportunities

FDA Initiative Forms Basis for Healthy Rx-to-OTC Switch Opportunities

In the not so distant past, the U.S. FDA has taken a rather conservative stance concerning Rx-to-OTC switches. Many potential categories have been discounted as not safe and/or effective without a physician’s prescription. This has compelled drug manufacturers to judiciously consider which drugs, if any, they would seek to switch given the necessary multi-million dollar expenditure on prerequisite clinical trials including self-selection, actual-use, and label-comprehension studies with consumers before the application and approval process with the FDA can even begin.  With its recent NSURE (Nonprescription Safe Use Regulatory Expansion) initiative, there are encouraging indications that FDA is becoming more receptive to allowing greater Rx-to-OTC switches.Continue reading

New Year Resolutions - Health and Wellness

New Year Resolutions – Health and Wellness

New year wishes and resolutions are closely tied to health and well-being. We wish for good health for others and want to get in better shape ourselves and therefore this phenomenon can translate into big bucks for many savvy companies promoting corresponding offers. Gyms are still full, and sales of health preparations increase. The digital helping hand also comes in a variety of apps, such as Fitocracy, Lose It, and My Last Cigarette. The most common new year resolutions include weight loss, quitting smoking, exercising, eating healthy, and a better work/life balance.Continue reading

The Markets for Excipients in the Middle East, Africa, and Southeast Asia

Excipient Blends: the new frontier in oral pharmaceutical applications.

Excipients are the unsung heroes of the oral solid-dosage-form (OSDF) pharmaceutical industry, seemingly content to remain out of the limelight and let the active ingredients take center stage. Now, a new breed of specially formulated blends could be just what the doctor ordered to help drug makers optimize production and potentially reduce the cost of producing life-saving medications.

Most consumers are completely unaware of the critical role excipients play in delivering the beneficial medicines millions rely on to fight diseases and stay healthy. Yet it is the fillers, binders, disintegrants, lubricants, and coatings that ensure the accurate, timed delivery of drugs required to safely maintain optimum active ingredient levels in our system and give the OSDF drugs we take every day their palpable size, texture, and flavor.Continue reading